Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 14 and 70 years old (including those exact ages)
- People diagnosed with acute myeloid leukaemia (AML) that has come back after treatment (relapsed) or has not responded to treatment (refractory), as defined by specific medical criteria set out by the World Health Organization
- People whose heart, liver, and kidney function test results fall within the acceptable ranges specified by the trial (confirm with trial site for exact values)
- People for whom a suitable matched donor is available for a bone marrow or stem cell transplant from another person
- People with a life expectancy of at least 3 months
- People who are well enough to carry out most daily activities, as measured by standard medical scoring tools (confirm with trial site)
- People who understand the study and are willing to sign a consent form
Who may not be able to join:
- People who have had serious allergic or other severe reactions to the study drugs being investigated
- People with a history of immune system deficiencies, inherited or acquired immune conditions, or who have previously had an organ transplant
- People who have experienced significant heart or blood vessel problems — such as high blood pressure complications, serious heart rhythm problems, a heart attack, heart failure, or stroke — within the past 6 months
- People who have had a moderate or major surgical procedure within the 4 weeks before joining the trial
- People with an active infection that is difficult to control, including serious fungal, bacterial, or viral infections (such as active HIV, hepatitis B, or hepatitis C) that require ongoing treatment
- People with leukaemia that has spread to the central nervous system and is currently active
- People who are pregnant or breastfeeding
- People who are currently taking part in another clinical trial
- People whom the trial doctors consider unsuitable for other medical reasons
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Depei Wu, Prof., The First Affiliated Hospital of Soochow University
Phone: 13057493105
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The cumulative incidence of neutrophil engraftment and platelet engraftment; The time to reconstitution of hematopoiesis; The cumulative incidence of transplant-related mortality (TRM)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.